Hinge Health (HNGE) EBITDA (2024 - 2026)

Hinge Health has disclosed EBITDA across 3 years of filings, most recently posting $34.8 million for Q1 2026.

• EBITDA for Q1 2026 came in at $34.8 million, up 103.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$524.7 million (down 3261.84% YoY), and the FY2025 annual result was -$528.3 million, down 4330.6% from the prior year.
• EBITDA came in at $34.8 million for Q1 2026 at Hinge Health, up from $27.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $34.8 million in Q1 2026 to a low of -$580.7 million in Q2 2025.
• The 3-year median for EBITDA is $6.6 million (2024), against an average of -$63.5 million.
• Across the five-year window, EBITDA slumped 3208.48% in 2025 and surged 103.74% in 2026, its largest moves.
• Hinge Health's EBITDA stood at $20.9 million in 2024, then soared by 30.35% to $27.3 million in 2025, then rose by 27.68% to $34.8 million in 2026.
• The last three EBITDA figures came in at $34.8 million (Q1 2026), $27.3 million (Q4 2025), and -$6.1 million (Q3 2025), per Business Quant data.